← Browse by Condition
Medical Condition

benign prostatic hyperplasia

Total Trials
7
Recruiting Now
7
Trial Phases
Phase 4

ClinicalMetric tracks all active clinical trials for benign prostatic hyperplasia sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — benign prostatic hyperplasia Clinical Trials

How many clinical trials are currently recruiting for benign prostatic hyperplasia?
ClinicalMetric currently tracks 7 actively recruiting clinical trials for benign prostatic hyperplasia, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for benign prostatic hyperplasia?
benign prostatic hyperplasia research spans Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a benign prostatic hyperplasia clinical trial?
Eligibility criteria for benign prostatic hyperplasia trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 4
1
Top Sponsors
Oslo University Hospital 1 trial
Thunder Bay Regional Health Research Institute 1 trial
University of Florence 1 trial
ProArc Medical 1 trial
Northwestern University 1 trial

Recruiting Clinical Trials

NCT04084938
Recruiting
Artery Embolization vs Operation of Benign Prostate Hyperplasia
Enrollment
140 pts
Location
Norway
Sponsor
Oslo University Hospital
View Trial →
NCT06546865
Recruiting
Slim Sheath 22F Holmium Laser Enucleation of the Prostate (HoLEP) vs 26 F Sheath HoLEP for BPH: RCT
Enrollment
142 pts
Location
Canada
Sponsor
Thunder Bay Regional Health Re...
View Trial →
NCT06564415
Recruiting
European Registry for Transperineal Laser Ablation of Prostate (TPLA) for Lower Urinary Tract Symptoms
Enrollment
2,500 pts
Location
Italy
Sponsor
University of Florence
View Trial →
NCT04627701
Recruiting
Omega Study: Evaluation of the Safety and Efficacy of the Omega System for the Treatment of BPH
Enrollment
26 pts
Location
Israel, New Zealand
Sponsor
ProArc Medical
View Trial →
NCT05898932
Recruiting
Enhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes
Enrollment
300 pts
Location
United States
Sponsor
Northwestern University
View Trial →
NCT04288427
Recruiting
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
Enrollment
120 pts
Location
United States
Sponsor
Beth Israel Deaconess Medical ...
View Trial →
NCT07650968 Phase 4
Recruiting
Tamsulosin Dose Escalation or Silodosin Switch Before Trial Without Catheter in BPH-Related Acute Urinary Retention
Enrollment
378 pts
Location
Egypt
Sponsor
Beni-Suef University
View Trial →

Related Conditions

lower urinary tract symptoms (2) post op complication (1) embolization therapeutic (1) transurethral resection of prostate syndrome (1) prostatic diseases (1) prostate hyperplasia (1) prostate disease (1) prostate hypertrophy (1) prostate pain (1) urinary obstruction (1) urinary tract disease (1) acute urinary retention (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology